KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $447.0 million.

  • Recursion Pharmaceuticals' Shares Outstanding (Diluted Average) rose 5817.94% to $447.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.0 million, marking a year-over-year increase of 5817.94%. This contributed to the annual value of $274.2 million for FY2024, which is 3192.31% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $447.0 million, which was up 5817.94% from $417.4 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $447.0 million during Q3 2025, and registered a low of $23.0 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $201.4 million (2023), whereas its average is $224.4 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first skyrocketed by 67245.54% in 2021, then surged by 290.89% in 2022.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $125.3 million in 2021, then surged by 40.04% to $175.5 million in 2022, then grew by 18.41% to $207.9 million in 2023, then skyrocketed by 31.92% to $274.2 million in 2024, then soared by 63.01% to $447.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $447.0 million for Q3 2025, versus $417.4 million for Q2 2025 and $402.8 million for Q1 2025.